MARKET

LYEL

LYEL

Lyell Immunopharma, Inc.
NASDAQ
25.84
+0.46
+1.81%
After Hours: 25.84 0 0.00% 16:04 02/13 EST
OPEN
25.48
PREV CLOSE
25.38
HIGH
27.24
LOW
25.20
VOLUME
105.61K
TURNOVER
--
52 WEEK HIGH
45.00
52 WEEK LOW
7.65
MARKET CAP
548.94M
P/E (TTM)
-1.1608
1D
5D
1M
3M
1Y
5Y
1D
The top-performing pharma and biotech stocks as group sees resurgence
Seeking Alpha · 4h ago
BRIEF-Lyell Immunopharma Announces Initiation Of Patient Dosing In First-Of-Its-Kind Phase 3 Car T-Cell Clinical Trial
Reuters · 1d ago
Lyell Immunopharma Launches Phase 3 Trial Comparing Ronde-cel to Approved CAR T Therapies in Large B-Cell Lymphoma
Reuters · 1d ago
Lyell Immunopharma Does First Participant In PiNACLE – H2H Phase 3 Study Evaluating Rondecabtagene Autoleucel
Benzinga · 1d ago
LYELL IMMUNOPHARMA INC - BLA SUBMISSION EXPECTED IN 2027
Reuters · 1d ago
Weekly Report: what happened at LYEL last week (0202-0206)?
Weekly Report · 4d ago
Weekly Report: what happened at LYEL last week (0126-0130)?
Weekly Report · 02/02 09:24
Weekly Report: what happened at LYEL last week (0119-0123)?
Weekly Report · 01/26 09:24
More
About LYEL
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Webull offers Lyell Immunopharma Inc stock information, including NASDAQ: LYEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LYEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LYEL stock methods without spending real money on the virtual paper trading platform.